EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, V8
Shareholders Approve Election of Tom Graney as Member of the Board of Directors
Reports Positive Safety & Immunogenicity at Week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
Extraordinary General Meeting Proxy Card
Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
Béatrice EHLERS NOTAIRE STATUTS
NASDAQ: ACIU | Annual General Meeting – June 11, 2026 Pioneering Precision Prevention Targeted Therapeutics for Neurodegenerative Diseases
To Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Initial Statement of Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload